EBOS Group Ltd stock (NZEBOE0001S6): Price move and sector outlook for US investors

EBOS Group Ltd shares dipped slightly on the ASX last week, highlighting ongoing interest in the Australian?New Zealand pharmaceutical wholesaler for US investors.

EBOS Group Ltd shares fell by about 1.9% on the Australian Securities Exchange on Friday, May 8, 2026, closing at A$17.49 after opening at A$17.83, according to market data compiled by StockInvest.us as of May 10, 2026.

As of May 10, 2026, the stock trades on the ASX under the ticker EBO and is also listed on the New Zealand Exchange, where it is quoted around NZ$21.80 per share with a trailing price?to?earnings ratio of roughly 16 and a gross dividend yield near 6%, according to NZX data as of May 10, 2026.

EBOS Group Ltd is the second?largest pharmaceutical wholesaler in Australia and New Zealand, supplying community pharmacies and hospitals, which together account for about 50% and 30% of group revenue, respectively, according to Morningstar as of May 10, 2026.

Drug pricing and wholesale margins for medicines covered by Australia’s Pharmaceutical Benefits Scheme are regulated, with wholesale gross margins capped at 7% for community pharmacy and 10% for hospitals, which tends to keep revenue growth in the low?single?digit range over time, Morningstar notes as of May 10, 2026.

Outside regulated pharmaceutical distribution, EBOS runs an animal health product wholesale, manufacturing and retail business, as well as third?party logistics services, which are smaller but higher?margin contributors to group revenue, Morningstar reports as of May 10, 2026.

Analysts expect EBOS Group to grow earnings at about 8.7% per year and revenue at roughly 4.6% per year over the medium term, with EPS projected to rise by around 9.5% annually, according to Simply Wall St’s forecast analysis as of May 10, 2026.

One broker has recently raised its fair?value estimate for EBOS Group from about A$32.64 to A$35.38, citing updated assumptions on revenue growth, profit margins and the future price?to?earnings multiple, Simply Wall St notes as of May 10, 2026.

EBOS Group’s market capitalization stands at roughly NZ$5.3 billion, with about 207 million ordinary shares on issue, according to NZX data as of May 10, 2026, positioning it as a mid?cap healthcare?distribution name in the Australasian region.

For US investors, EBOS Group offers indirect exposure to the Australian and New Zealand healthcare and pharmaceutical?distribution sectors, which are closely tied to government?funded medicine schemes and demographic aging trends, Morningstar highlights as of May 10, 2026.

As of: May 10, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: EBOS Group Ltd
• Sector/industry: Healthcare / Medical Distribution
• Headquarters/country: Australia and New Zealand
• Core markets: Australia, New Zealand
• Key revenue drivers: Pharmaceutical wholesaling, animal health products, third?party logistics
• Home exchange/listing venue: ASX (EBO), NZX (EBO)
• Trading currency: Australian dollar (ASX), New Zealand dollar (NZX)

EBOS Group Ltd: core business model

EBOS Group Ltd operates as a diversified healthcare and pharmaceutical?products company, with its largest segment being pharmaceutical wholesaling across Australia and New Zealand, according to Morningstar as of May 10, 2026.

The company supplies branded and generic medicines to community pharmacies and hospitals, which together generate about 80% of group revenue, with the remaining share coming from animal health, consumer health and logistics services, Morningstar notes as of May 10, 2026.

Because a large portion of its pharmaceutical business is tied to Australia’s Pharmaceutical Benefits Scheme, EBOS faces regulated wholesale margins and periodic price reforms that can compress margins and limit top?line growth, Morningstar explains as of May 10, 2026.

At the same time, the company benefits from relatively stable demand for essential medicines and recurring contracts with pharmacies and hospitals, which supports predictable cash flows despite the regulated environment, Morningstar observes as of May 10, 2026.

Main revenue and product drivers for EBOS Group Ltd

Pharmaceutical wholesaling remains EBOS Group’s primary revenue driver, with community pharmacies and hospitals each representing a major customer segment, according to Morningstar as of May 10, 2026.

Within this segment, the company earns regulated wholesale margins on PBS?listed medicines, while also handling non?PBS and specialty products that can carry higher markups, Morningstar reports as of May 10, 2026.

Outside pharmaceuticals, EBOS runs an animal health business that includes wholesale distribution, manufacturing and retail of veterinary and livestock products, which contributes a smaller but higher?margin share of revenue, Morningstar notes as of May 10, 2026.

The group also provides third?party logistics and supply?chain services to other healthcare and consumer?goods companies, leveraging its warehousing and distribution network across Australia and New Zealand, Morningstar highlights as of May 10, 2026.

Why EBOS Group Ltd matters for US investors

For US investors, EBOS Group offers a way to gain exposure to the Australian and New Zealand healthcare?distribution sectors without directly investing in domestic US wholesalers, Morningstar notes as of May 10, 2026.

These markets are characterized by government?funded medicine schemes, aging populations and steady demand for essential drugs, which can support relatively stable revenue and cash flows over time, Morningstar explains as of May 10, 2026.

At the same time, US investors should be aware that EBOS is sensitive to regulatory changes in drug pricing and reimbursement, as well as to macroeconomic conditions in Australia and New Zealand, which can affect consumer and government spending on healthcare, Morningstar warns as of May 10, 2026.

Conclusion

EBOS Group Ltd has seen its share price dip slightly on the ASX in early May 2026, reflecting ongoing trading in a mid?cap healthcare?distribution name with regulated pharmaceutical margins and diversified animal?health and logistics operations, according to market data and Morningstar as of May 10, 2026.

Analysts project modest revenue growth and stronger earnings growth over the medium term, supported by higher?margin non?pharmaceutical segments and steady demand for essential medicines in Australia and New Zealand, Simply Wall St notes as of May 10, 2026.

US investors considering EBOS Group should weigh the stability of its regulated pharmaceutical business against exposure to regulatory risk and regional economic conditions, while also noting that the stock trades on Australian and New Zealand exchanges and is denominated in local currencies, Morningstar highlights as of May 10, 2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.